Pharmacology of 1-(3,4-dichlorobenzyl)-3,4,5,6-tetrahydro-2(1H)-pyrimidone, a novel antidepressant compound with antianxiety activity.
1-(3,4-dichlorobenzyl)-3,4,5,6-tetrahydro-2(1H)-pyrimidone (I) was evaluated in selected pharmacological tests, and its activity was compared to that of some clinically useful psychotropic drugs. Based on the results, it is evident that I has a unique profile of antidepressant and antianxiety activities that are evident in the same dose range. The mechanism of its antidepressant activity is proposed to be similar to the tricyclic antidepressants, that is, inhibition of norepinephrine uptake. Neither I nor the tricyclic antidepressants possess monoamine oxidase-inhibiting activity. However, unlike the tricyclic antidepressants, I is devoid of any significant anticholinergic activity and presumably is free of anticholinergic side effects.
D000818:Animals; D014151:Anti-Anxiety Agents; D000928:Antidepressive Agents; D001923:Brain Chemistry / Q000187:drug effects; D002415:Cats; D005260:Female; D006634:Histamine H1 Antagonists; D006801:Humans; D007928:Lethal Dose 50; D008297:Male; D051379:Mice; D008996:Monoamine Oxidase Inhibitors; D018377:Neurotransmitter Agents / Q000378:metabolism; D009541:Nictitating Membrane / Q000187:drug effects; D010276:Parasympatholytics; D010433:Pentylenetetrazole / Q000037:antagonists & inhibitors; D011744:Pyrimidinones / Q000494:pharmacology*; D051381:Rats; D013239:Stereotyped Behavior / Q000187:drug effects; D013747:Tetrabenazine / Q000037:antagonists & inhibitors
D014151:Anti-Anxiety Agents; D000928:Antidepressive Agents; D006634:Histamine H1 Antagonists; D008996:Monoamine Oxidase Inhibitors; D018377:Neurotransmitter Agents; D010276:Parasympatholytics; D011744:Pyrimidinones; C026983:1-(3,4-dichlorobenzyl)-3,4,5,6-tetrahydro-2(1H)-pyrimidone; D010433:Pentylenetetrazole; D013747:Tetrabenazine